10 recruiting, 8 active not recruiting, 6 terminated, 5 completed. 26 Phase 2, 17 Phase 1, 1 Phase 3.
Follow Onureg: new trials by email Literature Review of Onureg trials Research Report on Onureg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML Azacitidine, APG1252 - AML | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 52 | 2026-05-22 | 2026-10-05 |
| A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax Tagraxofusp, Azacitidine (AZA), Venetoclax - Acute Myeloid Leukaemia (AML), Leukemia | Phase 1 / Phase 2 | Recruiting | Jacqueline Garcia, MD | 31 | 2026-02-02 | 2026-02-05 |
| Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome Azacitidine Level -1, Azacitidine Level 0, Azacitidine Level 1 - Myelodysplastic Syndromes | Phase 1 | Recruiting | Medical College of Wisconsin | 12 | 2025-01-10 | 2026-04-03 |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment Cytarabine, Venetoclax, CPX-351 - Leukemia, Myeloid, Acute | Phase 2 | Not yet recruiting | Eastern Cooperative Oncology Group | 184 | 2024-10-23 | 2024-07-03 |
| Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Withdrawn | City of Hope Medical Center | 2024-10-09 | 2024-09-19 | |
| Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia Venetoclax, Azacitidine, Mitoxantrone - Leukemia, Myeloid Leukemia | Phase 1 | Recruiting | University of Colorado, Denver | 30 | 2024-07-21 | 2026-01-15 |
| A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies Onureg - Hepatic Insufficiency, Neoplasms | Phase 1 | Terminated | Bristol-Myers Squibb | 2 | 2024-07-12 | 2026-01-12 |
| Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML) Azacitidine, Onureg - Acute Myeloid Leukaemia | Phase 1 | Completed | Hikma Pharmaceuticals LLC | 32 | 2024-05-02 | 2025-09-26 |
| Cladribine Venetoclax in Monocytic AML Cladribine, Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 2 | Active not recruiting | University of Colorado, Denver | 10 | 2024-02-08 | 2026-08-25 |
| Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia AzaCITIDine Oral Tablet, Xospata - AML, Adult, Refractory AML | Phase 2 | Recruiting | French Innovative Leukemia Organisation | 33 | 2024-01-13 | 2025-03-24 |
| Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients oral azacitidine (CC-486) - Acute Myeloid Leukemia | Phase 2 | Withdrawn | Yale University | 2023-11-01 | 2023-12-26 | |
| IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) Azacitidine, Biopsy, Enasidenib - Acute Myeloid Leukemia | Phase 2 | Recruiting | Alice Mims | 125 | 2022-09-13 | 2026-06-23 |
| An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission CC-486, Placebo - Leukemia, Myeloid, Acute | Phase 2 | Active not recruiting | Bristol-Myers Squibb | 34 | 2022-08-19 | 2026-04-28 |
| Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome Azacitidine, Quality-of-Life Assessment, Questionnaire Administration - Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome | Phase 2 | Active not recruiting | Uma Borate | 33 | 2022-06-23 | 2026-05-14 |
| Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure Azacitidine, Decitabine, Venetoclax - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 2 | Recruiting | Brian Jonas | 20 | 2022-02-09 | 2024-05-29 |
| A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission Oral Azacitidine, Placebo - Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Bristol-Myers Squibb | 19 | 2022-01-17 | 2026-02-11 |
| Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Azacitidine, Seclidemstat - Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1 | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 24 | 2021-07-07 | 2026-09-18 |
| Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia Azacitidine, Uproleselan, Venetoclax - Acute Myeloid Leukemia | Phase 1 | Terminated | Brian Jonas | 16 | 2021-07-02 | 2026-02-23 |
| Study of Magrolimab Combinations in Participants With Myeloid Malignancies Magrolimab, Azacitidine, Venetoclax - Myeloid Malignancies | Phase 2 | Terminated | Gilead Sciences | 54 | 2021-06-28 | 2025-03-20 |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 422 | 2021-05-20 | 2026-10-27 |
Showing 20 of 33. Sign in to see all of them.
Leukemia, Myeloid, Acute (22) · Myelodysplastic Syndromes (8) · Leukemia, Myelomonocytic, Chronic (5) · Hematologic Neoplasms (3) · Leukemia (2) · Leukemia, Monocytic, Acute (2) · Myeloproliferative Disorders (2) · Neoplasms (2) · Anemia, Refractory, with Excess of Blasts (1) · Hematologic Diseases (1) · Hepatic Insufficiency (1) · Hypereosinophilic Syndrome (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Erythroblastic, Acute (1) · Leukemia, Megakaryoblastic, Acute (1)
M.D. Anderson Cancer Center (10) · National Cancer Institute (NCI) (5) · Bristol-Myers Squibb (3) · Brian Jonas (2) · University of Colorado, Denver (2) · Alice Mims (1) · Celgene (1) · City of Hope Medical Center (1) · Eastern Cooperative Oncology Group (1) · French Innovative Leukemia Organisation (1) · Gilead Sciences (1) · Hikma Pharmaceuticals LLC (1) · Jacqueline Garcia, MD (1) · Medical College of Wisconsin (1) · Uma Borate (1)
United States (27) · United Kingdom (2) · Argentina (1) · Australia (1) · China (1) · Colombia (1) · France (1) · Germany (1) · Japan (1) · Saudi Arabia (1) · Spain (1)
Brian A Jonas (3) · Nicholas Short (2) · Alice S Mims, MD (1) · Andrew Kent, MD, PhD (1) · Betul Oran (1) · Christine McMahon, MD (1) · Courtney DiNardo, MD (1) · Ehab Atallah, MD (1) · Elizabeth A Brem (1) · Guillermo Garcia-Manero (1) · Guillermo M Bravo (1) · Guru Subramanian Guru Murthy, MD, MS (1) · Jacqueline Garcia, MD (1)
PMID 31212080, PMID 34686472, PMID 34889407, PMID 35704787, PMID 36063832, PMID 36841758, PMID 37422688, PMID 38277619, PMID 40073835, PMID 40364806, PMID 40513054, PMID 41779512, PMID 42035228, PMID 42200455
P30CA093373 (2), 2023 (1), P30CA033572 (1), R01CA262496 (1), T32CA233414 (1), U10CA031946 (1), U10CA180821 (1), U10CA180888 (1), UM1CA186691 (1), UM1CA186717 (1)